PharmiWeb27m
Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...
PharmiWeb25m
Carterra Ships Its First Ultra Biosensor Platform and Finishes 2024 with Double-digit Growth and Record Revenues
Carterra Inc., the world leader in enabling high-throughput biology, announced today that it has sold and shipped its first Carterra Ultra™ biosensor platform. Announced in September 2024, the Ultra ...
PharmiWeb40m
Transplantable piezoelectric biomaterial offers new treatment potential for central nervous system injuries and neurodegenerative diseases
A UK research team has created a new material for treating central nervous system injuries and neurodegenerative diseases, offering hope of new therapies to regain lost motor, sensory or cognitive ...
PharmiWeb29m
4SC announces update relating to Resminostat’s (Kinselby) Marketing Authorisation Application
SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that it had submitted its ...
PharmiWeb24m
Novartis gene therapy poised to expand SMA treatment landscape, says GlobalData
Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in a Phase III STEER study (NCT05089656) ...
PharmiWeb22m
Evaluate Releases 2025 Preview for Pharma Market
Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.